Your browser doesn't support javascript.
loading
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Jindal, Tanya; Zhang, Li; Deshmukh, Prianka; Reyes, Kevin; Chan, Emily; Kumar, Vipul; Zhu, Xiaolin; Maldonado, Edward; Feng, Stephanie; Johnson, Michelle; Angelidakis, Austin; Kwon, Daniel; Desai, Arpita; Borno, Hala T; Bose, Rohit; Wong, Anthony; Hong, Julian; Carroll, Peter; Meng, Maxwell; Porten, Sima; Aggarwal, Rahul; Small, Eric J; Fong, Lawrence; Chou, Jonathan; Friedlander, Terence; de Kouchkovsky, Ivan; Koshkin, Vadim S.
  • Jindal T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Zhang L; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Deshmukh P; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Reyes K; Department of Medicine, School of Medicine, University of California San Francisco, San Francisco, CA.
  • Chan E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Kumar V; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Zhu X; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Maldonado E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Feng S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Johnson M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Angelidakis A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Kwon D; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Desai A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Borno HT; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Bose R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Wong A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Hong J; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Carroll P; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Meng M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Porten S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Aggarwal R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Fong L; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Chou J; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Friedlander T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • de Kouchkovsky I; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Electronic address: Ivan.DeKouchkovsky@ucsf.edu.
  • Koshkin VS; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Electronic address: Vadim.koshkin@ucsf.edu.
Clin Genitourin Cancer ; 21(5): e394-e404, 2023 10.
Article en En | MEDLINE | ID: mdl-37316414
ABSTRACT

INTRODUCTION:

Urothelial carcinoma with squamous differentiation (UCS) is associated with increased resistance to chemotherapy, but outcomes associated with newer therapies approved in this space over the last 5 to 10 years are less well defined. We investigated clinical outcomes and molecular profiling of patients with UCS treated with an immune checkpoint inhibitor (ICI) and/or Enfortumab vedotin (EV). PATIENTS AND

METHODS:

We undertook a retrospective analysis of UC patients treated with ICI and/or EV. Objective response rate (ORR), progression free survival (PFS) and overall survival (OS) were compared between pure UC (pUC) and UCS using X2 and log-rank tests, respectively. Prevalence of the most commonly detected somatic alterations were also compared between the 2 histologic subgroups.

RESULTS:

A total of 160 patients (40 UCS, 120 pUC) were identified for this analysis. Among 151 patients treated with ICI (38 UCS, 113 pUC), UCS patients had a shorter mPFS (1.9 vs. 4.8 months, P < 0.01) and mOS (9.2 vs. 20.7 months, P < 0.01) compared to pUC. Among 37 patients treated with EV (12 UCS, 25 pUC), UCS patients had a lower ORR (17% vs. 70%, P < 0.01) and shorter mPFS (3.4 vs. 15.8 months, P < 0.01). UCS samples were enriched for CDKN2A, CDKN2B, PIK3CA, while pUC samples were enriched for ERBB2 alterations.

CONCLUSION:

In this single-center retrospective analysis, patients with UCS had a distinct somatic genomic profile relative to patients with pUC. Patients with UCS also had inferior outcomes to ICIs and EV compared to patients with pUC.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Escamosas / Carcinoma de Células Transicionales Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Escamosas / Carcinoma de Células Transicionales Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article